Prognostic Impact of Pre-Transplant Chromosomal Aberrations Detected By SNP-Array in Patients Undergoing Unrelated Donor Hematopoietic Cell Transplant for Acute Myeloid Leukemia

High-resolution genome-wide SNP-arrays detect large chromosomal aberrations including copy-neutral loss of heterozygosity (CNLOH), which is not captured in conventional cytogenetics.
Source: Biology of Blood and Marrow Transplantation - Category: Hematology Authors: Tags: 13 Source Type: research

Related Links:

Standardized phase angle (SPhA) is a tool used to estimate body composition and cell membrane integrity. Lower baseline SPhA was associated with increased incidence of 60 ‐day mortality in univariable (odds ratio [OR] = 5.25; 1.35, 20.44;P = .02) but not multivariable analysis (OR = 3.12; 0.67, 14.48;P = .15) adjusted for age, creatinine, and cytogenetics. Standardized phase angle is a rapid, noninvasive, and objective measure that may be used to inform risk stratification in adult acute leukemia patients. AbstractStandardized phase angle (SPhA) is a tool used to estimate body comp...
Source: Cancer Medicine - Category: Cancer & Oncology Authors: Tags: ORIGINAL RESEARCH Source Type: research
The planned trial will investigate the safety and efficacy of the novel multi-tumor associated antigen T-cell therapy in patients with post-transplant acute myeloid leukemia.
Source: CancerNetwork - Category: Cancer & Oncology Authors: Source Type: news
In conclusion, the patients with PTM had comparable outcomes with regard to mortality and cancer-specific mortality compared with those without PTM. This study showed that the patients with PTM can obtain an acceptable outcome after LDLT when carefully selected. PMID: 32023575 [PubMed - as supplied by publisher]
Source: BioScience Trends - Category: Biomedical Science Tags: Biosci Trends Source Type: research
AbstractPurpose of ReviewThis review discusses the current standard of care for incorporation of FLT3 TKIs and HCT into the treatment of FLT3-ITD AML. Additionally, this review provides an approach to the patient with relapsed/refractory disease.Recent FindingsOver the last decade, the routine use of HCT as consolidative therapy and the development of FLT3 TKIs have significantly improved remission rates and overall survival. The value and challenges of MRD assessment in FLT3 disease are discussed and current mechanisms of relapse are explored, as are the ongoing questions in the field that current clinical trials are seek...
Source: Current Hematologic Malignancy Reports - Category: Hematology Source Type: research
Abstract New therapeutic strategies are needed for pediatric acute myeloid leukemia to reduce disease recurrence and treatment-related morbidity. The Children's Oncology Group Phase III AAML1031 trial tested whether the addition of bortezomib to standard chemotherapy improves survival in pediatric patients with newly diagnosed acute myeloid leukemia. AAML1031 randomized patients younger than 30 years of age with de novo acute myeloid leukemia to standard treatment with or without bortezomib. All patients received the identical chemotherapy backbone with either four intensive chemotherapy courses or three courses f...
Source: Haematologica - Category: Hematology Authors: Tags: Haematologica Source Type: research
Conclusions Our results suggest that giving levetiracetam at 1000  mg q12h p.o starting 12 h before the administration of i.v. busulfan until 48 h after the last dose, can be used as an alternative in the prevention of busulfan-induced seizures in adults.
Source: International Journal of Clinical Pharmacy - Category: Drugs & Pharmacology Source Type: research
Publication date: Available online 3 February 2020Source: CytotherapyAuthor(s): Yuxia Wang, Xiaolu Sun, Shengnan Yuan, Shuaibing Hou, Tengxiao Guo, Yajing Chu, Tianxiang Pang, Hongbo R. Luo, Weiping Yuan, Xiaomin WangAbstractEnhanced interleukin-1β (IL-1β) signaling is a common event in patients with acute myeloid leukemia (AML). It was previously demonstrated that chronic IL-1β exposure severely impaired hematopoietic stem cell (HSC) self-renewal capability in mice and promoted leukemia cell growth in primary AML cells. However, the role of IL-1β in the murine bone marrow (BM) niche remains unclear. He...
Source: Cytotherapy - Category: Cytology Source Type: research
PMID: 32005652 [PubMed - in process]
Source: Haematologica - Category: Hematology Authors: Tags: Haematologica Source Type: research
Publication date: Available online 2 January 2020Source: Clinical Lymphoma Myeloma and LeukemiaAuthor(s): Fouad Kerbage, Riwa Sakr, Valerie Lapierre, Kamelia Alexandrova, Tereza Coman, Severine Leroux, Nolwenn Lucas, Sylvain Pilorge, Eric Solary, Jean-henri Bourhis, Cristina Castilla-LlorenteAbstractAllogeneic hematopoietic cell transplantation (AHCT) represents the only curative therapy for many hematological malignancies. The graft versus leukemia effect, driven by donor T cells, plays a major role in its curative potential. This effect is sometimes very evident when patients with acute myeloid leukemia and myelodysplasi...
Source: Clinical Lymphoma Myeloma and Leukemia - Category: Cancer & Oncology Source Type: research
Allogeneic stem cell transplantation (allo-SCT) is the only curative treatment option for many hematological diseases, including acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS). Outcomes of allo-SCT have improved with better supportive care, reduced intensity conditioning regimens, and use of alternative stem cell donor sources. [1] However, relapsed disease after allo-SCT remains a major cause of treatment failure, occurring in approximately 40% of AML cases, most of which occur within the first year.
Source: Biology of Blood and Marrow Transplantation - Category: Hematology Authors: Source Type: research
More News: Acute Leukemia | Acute Myeloid Leukemia | Biology | Hematology | Leukemia | Transplants